Avoro Capital Advisors
Superinvestor profile · Rank #39 by reported 13F value (2026 Q2 filers) · CIK 0001633313 · All profiles
Founded 2010New York, New York, United StatesLong-term life sciences / biotechnology investing in emerging biotech companiesKey person: Behzad Aghazadeh
Reported 13F value
$11.1B
Period 2026-06-30 · Filed 2026-08-14
Positions
26
Top 10 = 79.5% of value
Clone performance
Withheld
Price coverage too low — see note
Latest-quarter activity
3 new · 9 exited
11 increased · 3 decreased
Clone performance withheld for this manager. Only 63.1% of the latest filing's reported value sits inside our price history, and on average 64% of each historical segment's weight is unpriced as well; the rest is mostly non-U.S. listings and small-cap names we cannot price reliably. A clone computed from the priced minority would misrepresent the disclosed portfolio, so we do not publish one. The snapshot, holdings and filing history below are complete as reported. Evidence: filing-by-filing dossier (PDF) · Methodology (PDF)
Top holdings — 2026 Q2 filing
| Ticker | Company | Weight | Reported value |
|---|---|---|---|
| UTHR | United Therapeutics Corp | 13.52% | $1.5B |
| ASND | Ascendis Pharma | 12.24% | $1.4B |
| KRYS | Krystal Biotech Inc | 9.64% | $1.1B |
| MDGL | Madrigal Pharmaceuticals Inc | 8.84% | $984M |
| ARGX | Argenx Se | 8.33% | $928M |
| ARWR | Arrowhead Pharmaceuticals Inc | 8.31% | $926M |
| KYMR | Kymera Therapeutics Inc | 7.70% | $857M |
| RVMD | Revolution Medicines Inc | 3.86% | $430M |
| CYTK | Cytokinetics Inc | 3.82% | $426M |
| CELC | Celcuity Inc | 3.19% | $356M |
As reported on the 2026-06-30 Form 13F (filed 2026-08-14). Full holdings and quarter changes: holdings page.
Filing history in this profile
Every clone input traces to one of these SEC filings. 63.1% of the latest filing's reported value is covered by our price history; the remainder is mostly non-U.S. listings, recent IPOs or delisted names and is excluded from the clone.
Background (founded / HQ / style) source: https://www.owler.com/company/avorocapital — Formerly known as venBio Select Advisor; portfolio manager and controlling person Behzad Aghazadeh per SEC filings; based at 110 Greene Street, New York.